我院近5年抗心绞痛药和血管扩张药使用分析  

Analysis of the application of anti-angina and vasodilating drugs in recent 5 years

作　　者：孙青 支文冰[1] 刘芳 罗俊[2] 袁月[1] 李维凤 SUN Qing;ZHI Wenbing;LUO Jun;YUAN Yue;LI Weifeng;LIU Fang(School of Pharmacy,Xi'an Jiaotong University,Xi'an 710061,China;The First Affiliated Hospital of Xi^an Jiaotong University,Xi'an 710061,China)

机构地区：[1]西安交通大学药学院,西安710061 [2]西安交通大学第一附属医院,西安710061

出　　处：《西北药学杂志》2018年第1期128-132,共5页Northwest Pharmaceutical Journal

摘　　要：目的分析我院近5年抗心绞痛药和血管扩张药的使用情况及用药趋势,为临床合理用药和医院药品规范管理提供参考依据。方法选取2012~2016年该院网络管理系统HIS数据库中抗心绞痛药和血管扩张药使用记录,根据WHO推荐的日用剂量、用药禁忌和药品说明书确定各种药品的日限定剂量(DDD),计算用药频度(DDDs)。结果 5年间该院抗心绞痛药和血管扩张药的使用总量呈增长趋势;注射剂占70%以上,且呈逐年上升趋势,缓、控释片剂的使用呈增长趋势。其中丹参川芎嗪注射液(5mL)金额排序第1,DDDs排序第3。结论抗心绞痛药和血管扩张药在该院的使用基本合理,熟知抗心绞痛和血管扩张药的应用范围,可提高临床合理用药率。To analyze the using situation and tendency of the drugs against angina pectoris as well as angiectasis,and to provide references for the hospital drugs management.We chose the anti-angina and vasodilating drugs using records from HIS database of network management system during 2012-2016,and calculated DDDs according to the WHO recommended daily dose,contraindication and drug instruction.In the five years,the anti-angina and vasodilating durgs application showed a trend of growing;the injection was more than 70%and was increasing;meanwhile,sustained release tablets and controlled release tablets was on the rise.The sales amount of Salvia M iltiorrhiza and Ligustrazine injection(5 mL)ranked in the first and the DDDs ranked in the No.3.It is reasonable for the use of anti-angina and vasodilating drugs in our hospital,and it is helpful to increase rationality in clinical on the basis of correct understanding the application scope of drugs.

关 键 词：抗心绞痛药 血管扩张药 用药频度 药品分类 合理用药 

分 类 号：R969.[医药卫生—药理学]